2840-LB: Semaglutide and Obstructive Sleep Apnea (OSA): A Post Hoc Analysis from SELECT
Diabetes · 05.06.2026 · 75 (Supplement_1)
DOI: 10.2337/db26-2840-lb ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes, erschienen am 05.06.2026. Verfasst von SILVIO INZUCCHI und 6 weiteren Autor:innen.
Abstract (Originalsprache)
Introduction and Objective: Semaglutide 2.4mg (sema) reduces MACE in people with obesity and CVD. Obstructive sleep apnea (OSA) is common in this population, but it is unknown if sema’s CV benefits are seen in those with OSA or if it can prevent OSA. This post hoc analysis of SELECT assessed the impact of sema on the risk of first occurrence of MACE (composite of non-fatal myocardial infarction, nonfatal stroke, or CV death) in patients with vs without OSA and explored the impact of sema on incident OSA.
Methods
SELECT included patients aged ≥45 years with BMI ≥27 and established CVD without diabetes. Preexisting OSA was identified by baseline questionnaire, with incident OSA captured by adverse event reports in those without baseline OSA. MACE risk was evaluated by OSA status and cumulative incidence analyses evaluated incident OSA for sema vs placebo.
Results
At baseline, 2,550 participants (14.5%) reported OSA. Sema was associated with numerically fewer MACE events vs placebo in those with (115 vs 121 events, HR [95% CI]=0.93 [0.72-1.20]) and without (454 vs 580 events, HR [95% CI]=0.78 [0.69-0.88]) OSA (interaction P=.203). Among those without OSA, sema was associated with a significantly lower risk of incident OSA (HR [95% CI]=0.48 [0.31-0.73]) (Figure).
Conclusion
The CV benefits of sema were consistent among those with and without OSA. Sema therapy was associated with a 52% reduction in incident OSA vs placebo. Disclosure S. Inzucchi: Consultant; Current; Boehringer Ingelheim International GmbH. Consultant; Ended; Bayer AG. Consultant; Current; Novo Nordisk, AstraZeneca, Corcept Therapeutics. N.M. Harder-Lauridsen: Employee; Current; Novo Nordisk A/S. S. Fjelstrup: Employee; Current; Novo Nordisk A/S. I. Neeland: Speaker's Bureau; Current; Boehringer Ingelheim International GmbH, Eli Lilly and Company, Bayer AG. Research Support; Current; American Heart Association, National Heart, Lung, and Blood Institute. Advisory Panel; Current; MJH Life Sciences. A. Traina: Employee; Current; Novo Nordisk. Stock/Shareholder; Current; Novo Nordisk. L. Wilson: Employee; Current; Novo Nordisk. D.H. Ryan: Advisory Panel; Current; Abbvie, Altimmune, Amgen, AstraZenica, Boehringer Ingelheim, Biohaven, Carmot/Roche/Genentech. Advisory Panel; Ended; eMed, Fractyl, Nestle. Consultant; Current; Pfizer, Source Bio, Protagonist, PPD, Regeneron, Regor. Advisory Panel; Current; Currax, Structure Therapeutics, Tenvie, Kailera. Speaker's Bureau; Current; LIlly, Novo Nordisk,. Other - I am a consultant to both and received stock options and consulting fees.; Current; Calibrate, Epitomee. Other - Data Monitoring Committee member; Current; CinRx, Rhythm, Lilly. Advisory Panel; Current; Viking, Weight Watchers, Wonder Health, Zealand. Other - ! received non-negotiable stock options from these companies years ago and have not worked for them in years.; Ended; Roman, Scientific Intake.
Zitieren
APA
INZUCCHI, S., HARDER-LAURIDSEN, N. M., FJELSTRUP, S., NEELAND, I., TRAINA, A., WILSON, L., & RYAN, D. H. (2026). 2840-LB: Semaglutide and Obstructive Sleep Apnea (OSA): A Post Hoc Analysis from SELECT. Diabetes, 75(Supplement_1). https://doi.org/10.2337/db26-2840-lb
Vancouver
INZUCCHI S, HARDER-LAURIDSEN NM, FJELSTRUP S, NEELAND I, TRAINA A, WILSON L, et al. 2840-LB: Semaglutide and Obstructive Sleep Apnea (OSA): A Post Hoc Analysis from SELECT. Diabetes. 2026;75(Supplement_1). doi:10.2337/db26-2840-lb
BibTeX
@article{INZUCCHI2026,
author = {INZUCCHI, SILVIO and HARDER-LAURIDSEN, NINA M. and FJELSTRUP, SØREN and NEELAND, IAN and TRAINA, ANDREA and WILSON, LAUREN and RYAN, DONNA H.},
title = {2840-LB: Semaglutide and Obstructive Sleep Apnea (OSA): A Post Hoc Analysis from SELECT},
journal = {Diabetes},
year = {2026},
volume = {75},
number = {Supplement_1},
doi = {10.2337/db26-2840-lb}
}
EUVIMED